Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGrau Vorster, Marta
dc.contributor.authorLopez Montañes, Maria
dc.contributor.authorCanto Puig, Ester
dc.contributor.authorVives Armengol, Joaquim
dc.contributor.authorOliver-Vila, Irene
dc.contributor.authorBarba Suñol, Pere
dc.contributor.authorRudilla Salvador, Francesc
dc.date.accessioned2021-09-08T07:38:53Z
dc.date.available2021-09-08T07:38:53Z
dc.date.issued2020-02-25
dc.identifier.citationGrau-Vorster M, López-Montañés M, Cantó E, Vives J, Oliver-Vila I, Barba P, et al. Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy. Front Immunol. 2020 Feb 25;11:271.
dc.identifier.issn1664-3224
dc.identifier.urihttp://hdl.handle.net/11351/6278
dc.descriptionAdoptive immunotherapy; Cytotoxicity; Virus specific T lymphocytes (VST)
dc.description.abstractImmunosuppressed patients are susceptible to virus reactivation or de novo infection. Adoptive immunotherapy, based on virus-specific T lymphocytes (VST), can prevent or treat viral diseases. However, donor availability, HLA-compatibility restrictions, high costs, and time required for the production of personalized medicines constitute considerable limitations to this treatment. Ex vivo rapid and large-scale expansion of VST, compliant with current good manufacturing practice (cGMP) standards, with an associated cell donor registry would overcome these limitations. This study aimed to characterize a VST product obtained through an expansion protocol transferable to cGMP standards. Antigenic stimulus consisted of cytomegalovirus (CMV) pp65 peptide pool-pulsed autologous dendritic cells (DCs) derived from monocytes. G-Rex technology, cytokines IL-2, IL-7, and IL-15, and anti-CD3 and anti-CD28 antibodies were used for culture. At day 14 of cell culture, the final product was characterized regarding T cell subsets, specificity, and functionality. The final product, comprised mainly CD4+ and CD8+ T lymphocytes (49.2 ± 24.7 and 42.3 ± 25.2, respectively). The culture conditions made it possible to achieve at least a 98.89-fold increase in pp65-specific CD3+ IFN-γ+ cells. These cells were specific, as pp65-specific cytotoxicity was demonstrated. Additionally, in complete HLA mismatch and without the presence of pp65, alloreactivity resulted in <5% cell lysis. In conclusion, a cGMP scalable process for the generation of a large number of doses of CMV-specific cytotoxic T cells was successfully performed.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Immunology;11
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectInfeccions per citomegalovirus
dc.subjectCèl·lules T
dc.subjectImmunoteràpia
dc.subject.meshImmunotherapy, Adoptive
dc.subject.meshT-Lymphocytes, Cytotoxic
dc.subject.meshCytomegalovirus Infections
dc.titleCharacterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fimmu.2020.00271
dc.subject.decsinfecciones por Citomegalovirus
dc.subject.decsinmunoterapia adoptiva
dc.subject.decslinfocitos T citotóxicos
dc.relation.publishversionhttps://doi.org/10.3389/fimmu.2020.00271
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Grau-Vorster M, López-Montañés M, Cantó E, Rudilla F] Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain. Grup de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vives J] Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain. Grup de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup d’Enginyeria tissular musculoesquelètica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Oliver-Vila I] Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain. [Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid32161589
dc.identifier.wos000524779300001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0011%2F0028
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR719
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record